IL27RA Antibody

Code CSB-PA953889
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using CSB-PA953889(IL27RA Antibody) at dilution 1/40, on the right is treated with fusion protein. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA953889(IL27RA Antibody) at dilution 1/40, on the right is treated with fusion protein. (Original magnification: ×200)
  • Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse thymus tissue, Mouse heart tissue, Primary antibody: CSB-PA953889(IL27RA Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
IL27RA
Alternative Names
Class I cytokine receptor antibody; CRL1 antibody; Cytokine receptor-like 1 antibody; I27RA_HUMAN antibody; IL-27 receptor subunit alpha antibody; IL-27R subunit alpha antibody; IL-27R-alpha antibody; IL-27RA antibody; IL27R alpha antibody; IL27R antibody; Il27ra antibody; Interleukin 27 receptor alpha chain precursor antibody; Interleukin 27 receptor antibody; Interleukin-27 receptor subunit alpha antibody; Protein CRL1 antibody; T cell cytokine receptor type 1 antibody; TCCR antibody; Type 1 T cell cytokine receptor antibody; Type I T-cell cytokine receptor antibody; WSX-1 antibody; WSX1 antibody; ZcytoR1 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Fusion protein of Human IL27RA
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:2000-1:5000
WB 1:200-1:1000
IHC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for IL27. Requires IL6ST/GP130 to mediate signal transduction in response to IL27. This signaling system acts through STAT3 and STAT1. Acts as a receptor for the neuroprotective peptide humanin as part of a complex with IL6ST/GP130 and CNTFR. Involved in the regulation of Th1-type immune responses. Also appears to be involved in innate defense mechanisms.
Gene References into Functions
  1. this study found elevated expression of IL-27 in human peripheral serum and elevated expression of its specific receptor (wsx-1) on fetal membranes in cases of preterm birth PMID: 28756371
  2. These results identify IL-27 and its specific receptor IL27RA as a critical immune axis for the antiviral immune response and as robust correlates of viral load and proviral reservoir size in mononuclear leukocytes in HIV infection. PMID: 28592538
  3. Findings demonstrated that IL-27 and IL-27R were elevated in multiple sclerosis lesions and that local IL-27 can modulate immune properties of astrocytes and infiltrating immune cells PMID: 26649511
  4. The significant expression of IL-27 in TB and the negative influence of IL-27R on T cell function demonstrate the pathway by which this cytokine/receptor pair is detrimental in TB. PMID: 26282876
  5. natural sIL-27Ralpha binds rIL-27, inhibits IL-27 binding to its cell surface receptor, and is a potent inhibitor of IL-27 signaling, as shown by its ability to specifically block IL-27-mediated STAT activation, at low molar excess over IL-27. PMID: 24771852
  6. Aberrant hypermethylation and reduced expression of IL27RA is associated with myelodysplastic syndromes. PMID: 22936014
  7. TCCR/WSX-1 is closely associated with angiogenesis and could serve as a novel therapeutic target in patients with age-related macular degeneration. PMID: 22312192
  8. Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity. PMID: 21631431
  9. WSX-1 is essential for transcriptional activation of STAT1 and for augmenting the induction of T-bet expression during initiation of Th1 cell differentiation. PMID: 12734330
  10. WSX-1 together with the cytokine receptor gp130 constitutes a functional signal-transducing receptor for IL-27. PMID: 14764690
  11. IL-27R possesses hematopoietic cell-transforming properties PMID: 18003935
  12. These results indicate that humanin protects neurons by binding to a complex or complexes involving CNTFR/WSX-1/gp130. PMID: 19386761
  13. Results reveal an interleukin 27-independent function of WSX1 sensitizing natural killer cell-mediated antitumor surveillance. PMID: 19549909

Show More

Hide All

Subcellular Location
Membrane; Single-pass type I membrane protein.
Protein Families
Type I cytokine receptor family, Type 2 subfamily
Tissue Specificity
Highly expressed in lymphoid tissues such as spleen, lymph nodes and peripheral blood leukocytes. Weakly expressed in other tissues examined including heart, brain, fetal and adult lung, liver, skeletal muscle, kidney, pancreas, prostate, testis, ovary, s
Database Links

HGNC: 17290

OMIM: 605350

KEGG: hsa:9466

STRING: 9606.ENSP00000263379

UniGene: Hs.132781

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*